J Frontier (2934 TSE Mothers) - - - - - - - - - - September 03,2021

A mail order company of health foods and medical products targeting to become a healthcare tech company

This report is an English translation of part of the report issued on August 31, 2021. For inquiries concerning the report, please contract info@stock-r.org

[2934 J Frontier Sector: Foods]

Fiscal Year	Net sales	YoY	Operating profit	YoY	Ordinary profit	YoY	Profit	YoY	EPS	BPS	DPS
	(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)	(yen)	(yen)	(yen)
May 2020	7,106	16.0	170	-53.7	174	-52.5	96	15.7x	25.1	219.3	0.0
May 2021	8,493	19.5	671	294.3	679	289.4	424	340.9	110.8	330.0	0.0
May 2022	f 10,497	23.6	853	27.1	817	20.4	523	23.2	118.7	-	0.0

Note: Non-consolidated basis. Figures for the fiscal year ending May 2022 are the company's forecasts. It conducted 1-to-2 stock split on July 7, 2021. Per share indicies are adjusted retroactively.

Engaged in Mail Order Sales of Health Foods and Medical Products as Core Business

J Frontier was launched in June 2008 as an internet advertisement agency in the healthcare field, and has been supporting sales promotions. In August 2012, based on its accumulated expertise in sales promotion, it has started planning, development and sales of in-house brand of health foods, and currently, mail order sales of health foods and medical products have become its core business.

In February 2021, it has started a medical platform service, SOKUYAKU, that provides services of medical institution searches, bookings and receiving online medical examinations by doctors, online dosing guidance by pharmacists and delivery of prescription drugs in a one-stop manner. This service is in a phase of full-scale business expansion.

The businesses of the company are classified into the three reporting segments of the healthcare sales business, the medical care sales business and the healthcare marketing business. The healthcare sales business, which handles mail order sales of health foods, accounts for around 70% of the entire net sales. The mail order sales of medical products is categorized in the medical care sales business, and the combined amount of mail order sales of health foods and medical products accounts for about 90% of the entire net sales.

Company Plan for the Fiscal Year Ending May 2022

For the fiscal year ending May 2022, the company expects net sales of 10,497 million yen (23.6% increase year on year, same hereinafter), operating profit of 853 million yen (27.1% increase), ordinary profit of 817 million yen (20.4% increase) and net profit of 523 million yen (23.2% increase). The company assumes a large revenue increase in the medical care sales business, in which its SOKUYAKU business is categorized.

J Frontier (2934 TSE Mothers) ------ September 03,2021

Financial Statements

Statement of income	Fiscal Year	May 2019		May 2020		May 2021	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Net sales		6,125	100.0	7,106	100.0	8,493	100.0
Cost of sales		972	15.9	1,611	22.7	1,864	22.0
Gross profit		5,153	84.1	5,494	77.3	6,628	78.0
Selling, general and administrative expenses		4,785	78.1	5,324	74.9	5,956	70.1
Operating profit		368	6.0	170	2.4	671	7.9
Non-operating income		0	-	6	-	10	-
Non-operating expenses		1	-	2	-	3	-
Ordinary profit		367	6.0	174	2.5	679	8.0
Profit before income taxes		111	1.8	134	1.9	678	8.0
Net profit		6	0.1	96	1.4	424	5.0

Balance sheet	Fiscal Year	May 2019		May 2020		May 2021	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets		1,807	94.7	1,863	91.7	2,407	92.8
Cash and deposits		953	49.9	908	44.7	1,638	63.1
Accounts receivable-trade		269	14.1	404	19.9	362	14.0
Inventories		478	25.1	396	19.5	350	13.5
Non-current assets		102	5.3	168	8.3	186	7.2
Property, plant and equipment		40	2.1	8	0.4	10	0.4
Intangible assets		13	0.7	40	2.0	18	0.7
Investments and other assets		48	2.5	120	5.9	157	6.1
Total assets		1,909	100.0	2,032	100.0	2,594	100.0
Current liabilities		994	52.1	1,114	54.8	1,318	50.8
Accounts payable - trade		31	1.6	102	5.0	107	4.1
Non-current liabilities		168	8.8	75	3.7	8	0.3
Net assets		745	39.0	842	41.5	1,267	48.9
Owners' equity		744	39.0	841	41.4	1,266	48.8

Statement of cash flows	Fiscal Year	May 2019	May 2020	May 2021
		(mn yen)	(mn yen)	(mn yen)
Cash flows from operating activities	es	13	218	830
Depreciation		6	12	5
Cash flows from investing activitie	S	-62	-165	-7
Cash flows from financing activities	s	130	-99	-93
Dividends paid		-	-	-
Net increase in cash and cash equ	iivalents	81	-45	729
Cash and cash equivalents		947	901	1,631

Note: Non-consolidated basis.

Source: Prepared by The Stock Research Center based on the notifiable prospectus.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■Supporting Members

Tokyo Stock Exchange, Inc. Nomura Securities Co., Ltd. Ernst & Young ShinNihon LLC Deloitte Touche Tohmatsu LLC A&A Partners TAKARA PRINTING CO., LTD. SMBC Nikko Securities Inc. Mizuho Securities Co., Ltd. ICMG Co., Ltd. SBI SECURITIES Co., Ltd. Ichiyoshi Securities Co., Ltd. PRONEXUS INC. Daiwa Securities Co. Ltd.
KPMG AZSA LLC
Grant Thornton Taiyo LLC
BDO Sanyu
Japan Securities Dealers Association
The Securities Analysts Association of Japan

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a
 wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular
 securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.